These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14758352)

  • 1. Intravesical therapy options for neurogenic detrusor overactivity.
    Reitz A; Schurch B
    Spinal Cord; 2004 May; 42(5):267-72. PubMed ID: 14758352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urinary incontinence: what's new in therapy?].
    Becher KF; Sieber CC
    Dtsch Med Wochenschr; 2015 Feb; 140(3):164-7. PubMed ID: 25658400
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions.
    Kuo HC
    J Urol; 2003 Sep; 170(3):835-9. PubMed ID: 12913711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.
    Silva C; Silva J; Ribeiro MJ; Avelino A; Cruz F
    Eur Urol; 2005 Oct; 48(4):650-5. PubMed ID: 15961217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
    Giannantoni A; Di Stasi SM; Stephen RL; Bini V; Costantini E; Porena M
    J Urol; 2004 Jul; 172(1):240-3. PubMed ID: 15201783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recalcitrant overactive bladder patient.
    Ghoniem GM
    Geriatrics; 2002 May; 57 Suppl 1():23-9. PubMed ID: 12040600
    [No Abstract]   [Full Text] [Related]  

  • 7. Refractory neurogenic detrusor overactivity.
    Cruz F; Silva C
    Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder rehabilitation in neurogenic and non-neurogenic detrusor dysfunction with intravesical electrotherapy.
    Helmut M; Gustav K; Dora M
    Ideggyogy Sz; 2005 Sep; 58(9-10):329-33. PubMed ID: 16252894
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity.
    Drake MJ
    BJU Int; 2008 Jul; 102 Suppl 1():11-6. PubMed ID: 18665973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity.
    Wyndaele JJ; Van Dromme SA
    Spinal Cord; 2002 Nov; 40(11):599-600. PubMed ID: 12411968
    [No Abstract]   [Full Text] [Related]  

  • 11. Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist.
    Santos-Silva A; Charrua A; Cruz CD; Gharat L; Avelino A; Cruz F
    Auton Neurosci; 2012 Jan; 166(1-2):35-8. PubMed ID: 22037502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of resiniferatoxin on neurogenic bladder].
    Liu TJ; Zhao MJ; Sha KF; Gao JZ
    Zhonghua Yi Xue Za Zhi; 2010 Jul; 90(26):1827-9. PubMed ID: 20979828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
    Von Zweigbergk M; Nordin B; Jonsson S
    Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
    [No Abstract]   [Full Text] [Related]  

  • 14. Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A.
    Charrua A; Avelino A; Cruz F
    Handb Exp Pharmacol; 2011; (202):345-74. PubMed ID: 21290235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis.
    Fjorback MV; Rijkhoff N; Petersen T; Nohr M; Sinkjaer T
    Neurourol Urodyn; 2006; 25(4):349-55. PubMed ID: 16673380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
    Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
    Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents.
    Schulte-Baukloh H; Knispel HH
    BJU Int; 2006 Sep; 98 Suppl 1():50-60; discussion 61. PubMed ID: 16911604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model.
    Atiemo H; Wynes J; Chuo J; Nipkow L; Sklar GN; Chai TC
    Urology; 2005 Mar; 65(3):622-6. PubMed ID: 15780404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical electromotive botulinum toxin type A administration: part I--Experimental study.
    Kajbafzadeh AM; Montaser-Kouhsari L; Ahmadi H; Sotoudeh M
    Urology; 2011 Jun; 77(6):1460-4. PubMed ID: 21168901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Physiology and evaluation of overactive bladder].
    Amarenco G; Leroi AM
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):358-66. PubMed ID: 12746711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.